Brandon Capital is a leading life science venture capital firm specialising in creating, funding and growing new biotech and healthcare companies. The firm is headquartered in Australia, where it is the largest life science investor with over AU $1.25bn of assets under management across six funds and an active portfolio of more than 30 companies, all with first- or best-in-class therapeutic approaches.

In 2021 Brandon Capital opened its UK office in Kings Cross to expand its growing portfolio in the UK and Europe. The UK team is led by Partner Dr Jonathan Tobin and is actively making seed, Series A, and Series B investments in UK biotech companies. First ticket sizes range from £2m to £15m, and the firm often takes lead roles in syndicates. In the UK, its portfolio includes Astronautx, Myricx Bio, NRG Therapeutics, Pathios and Pheon Therapeutics.

The firm has an excellent track record of successfully exiting companies, the founders of which have all chosen to work with Brandon a second time on new opportunities. Brandon has a collaborative and transparent culture, and we are motivated by converting high-quality science into important medicines to treat serious diseases.